(R) -Azasetron (besylate)

(R) -Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R) -Azasetron besylate reduces Cisplatin (HY-17394) -induced hearing loss and cochlear damage[1][2].

Product Specifications

CAS Number

[2025360-91-0]

Product Name Alternative

SENS-401

UNSPSC

12352005

Target

Phosphatase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/r-azasetron-besylate.html

Purity

98.78

Solubility

DMSO : ≥ 200 mg/mL

Smiles

O=S(O)(C1=CC=CC=C1)=O.O=C(C2=C(OCC(N3C)=O)C3=CC(Cl)=C2)N[C@H]4CN5CCC4CC5

Molecular Formula

C23H26ClN3O6S

Molecular Weight

507.99

References & Citations

[1]Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours. Otol Neurotol. 2019 Feb;40 (2) :254-263.|[2]Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38 (9) :1355-1361.